Clinical Trial Update: Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating LIB003 in combination with Inclisiran for efficacy and safety in high-risk cardiovascular disease patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Hypercholesterolemia

Drugs mentioned

• Inclisiran (inclisiran)
• LIB003

Snippet

Sponsor: LIB Therapeutics LLC | Conditions: Hypercholesterolemia, Atherosclerotic Ischemic Disease | Phase 3 | Status: COMPLETED